Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting. Uprety D. J Thorac Oncol 2021;16:371-374.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Uprety D. Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting. J Thorac Oncol 2021;16:371-374.
PMID: 33641721